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Background: Survival rates for oesophageal adenocarcinoma (OAC) remain disappointingly poor and current
conventional treatment modalities have minimal impact on long-term survival. This is partly due to a lack of
understanding of the molecular changes that occur in this disease. Previous studies have indicated that the
transcription factor FOXM1 is commonly upregulated in this cancer type but the impact of this overexpression on
gene expression in the context of OAC is largely unknown. FOXM1 does not function alone but works alongside
the antagonistically-functioning co-regulatory MMB and DREAM complexes.
Methods: To establish how FOXM1 affects gene expression in OAC we have identified the FOXM1 target gene
network in OAC-derived cells using ChIP-seq and determined the expression of both its coregulatory partners and
members of this target gene network in OAC by digital transcript counting using the Nanostring gene expression
assay.
Results: We find co-upregulation of FOXM1 with its target gene network in OAC. Furthermore, we find changes in
the expression of its coregulatory partners, including co-upregulation of LIN9 and, surprisingly, reduced expression
of LIN54. Mechanistically, we identify LIN9 as the direct binding partner for FOXM1 in the MMB complex. In the
context of OAC, both coregulator (eg LIN54) and target gene (eg UHRF1) expression levels are predictive of disease
stage.
Conclusions: Together our data demonstrate that there are global changes to the FOXM1 regulatory network in
OAC and the expression of components of this network help predict cancer prognosis.
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Oesophageal adenocarcinoma (OAC) is becoming increas-
ingly common in the Western world and yet five year sur-
vival rates remain low (<10%) [1]. Early detection, through
the use of molecular markers would help with disease
management, as would the identification of new potential
therapeutic targets. However compared to other cancers,
our knowledge of the deregulated cellular pathways in
OACs is much less developed. More recently, genome/
systems-wide approaches have been used to accelerate our* Correspondence: a.d.sharrocks@manchester.ac.uk
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unless otherwise stated.understanding of the molecular defects in OACs [2].
For example, microarray studies have identified gene
signatures that are of prognostic value [3,4] and recent
genome-sequencing studies have uncovered new muta-
tions commonly found in OAC samples [5] and associ-
ated with disease progression [6].
Many studies have linked the transcription factor
FOXM1 to a broad range of different human cancers
(reviewed in [7]), including OAC [8]. Moreover, genomic
sequencing approaches have revealed defects in the
broader FOXM1 regulatory network in the context of
high grade serous ovarian cancer [9]. FOXM1 is a key
regulator of periodic gene transcription at the G2-M
phase of the cell cycle [7,10] and therefore thought to beal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Consistent with this, part of the FOXM1 regulatory
network encoding kinetochore-associated proteins was
shown to be coordinately upregulated across a range of
cancers [11] and another study identified the FOXM1
target gene CENPF as synergistically interacting with
FOXM1 to drive prostate cancer malignancy [12]. How-
ever, while these findings further emphasise a core role
for cell cycle-associated FOXM1 target genes in cancer
progression, other studies in gliomas have implicated
FOXM1 in promoting the nuclear translocation of β-
catenin, resulting in activation of a programme of Wnt
target genes [13]. This finding is suggestive of alternative
roles for FOXM1 in the context of cancer. Indeed,
FOXM1 is recruited to DNA in lymphoblastoid cells by
NF-kB [14] and FOXM1 co-operates with ERα in driving
gene expression in the context of breast cancer [15].
In this study, we took an unbiased approach using
ChIP-seq to identify FOXM1 target genes in OAC-
derived cells. Subsequently, we studied the expression of
a cohort of novel FOXM1 target genes across OAC-
derived patient samples. In addition, we investigated the
expression of FOXM1 coregulatory partners from the
MMB and DREAM complexes in the same patient sam-
ples. FOXM1 works synergistically with the MMB com-
plex to drive cell cycle gene expression whereas the
DREAM complex functions in an antagonistic manner
on the same target genes [16-18]. Our results reveal
widespread co-ordinate deregulated expression of the
FOXM1 regulatory network in OAC, including changes
in both co-regulators (eg LIN54) and target genes (eg
UHRF1) which have potential diagnostic utility in identi-
fying late-stage cancer.
Results
Identification of the FOXM1 cistrome in OAC cells
FOXM1 and several of its well established target genes
have been shown to be co-overexpressed in OAC [8]. To
determine how widespread this co-overexpression is, we
first sought to identify all of the direct FOXM1 targets
by performing ChIP-seq analysis in the OAC-derived
OE33 cell line. In total, 517 high confidence peaks were
identified in two independent experiments (Additional
file 1: Table S1; for examples see Additional file 2:
Figure S1A). We tested a random selection of FOXM1
target regions of varying tag densities by ChIP-qPCR
and validated FOXM1 occupancy at 5 out of 6 regions
(Additional file 2: Figure S1B). In common with other
FOXM1 ChIP-seq studies in different cell types, a
large proportion of the binding regions were found in
promoter-proximal regions (Figure 1A; [15,16,19]). More-
over gene ontology analysis identified cell cycle-associated
GO terms as enriched in FOXM1 target genes, in keeping
with its known role in controlling cell cycle events(Figure 1B; reviewed in [20]). Next we compared the
FOXM1 binding profile in OE33 cells to previous data de-
rived from osteosarcoma-derived U2OS cells [16]. To pro-
vide the biggest possible coverage of FOXM1 binding
regions in OE33 cells, the sequencing reads from the two
independent ChIP-seq experiments were combined, peaks
were recalled and 1716 FOXM1 binding regions were
identified (Additional file 1: Table S1). Using this high
coverage dataset, we identified 175 binding regions that
were commonly occupied in both OE33 and U2OS cells
(Figure 1C and D; Additional file 1: Table S1). However,
1541 FOXM1 binding regions were uniquely present in
OE33 cells, although a weak tag density profile could be
observed in U2OS cells around these peak summits
(Figure 1C and D). To validate this differential binding
across cell types, we used ChIP-qPCR, and identified the
HIST1H3G regulatory region as specifically bound by
FOXM1 in OE33 cells whereas the opposite was true for
the ZNF507 locus (Figure 1E). Regions bound in both cell
types were validated as strongly occupied in OE33 and
U2OS cells by ChIP-qPCR (CENPF and FZR1) (Figure 1E).
Having established FOXM1 binding, we next wanted to
establish FOXM1-dependent gene regulation at its target
loci. We reasoned that as FOXM1 is a transcriptional acti-
vator, its target genes should be co-upregulated in cancer
cells. We therefore compared the expression of FOXM1 in
a microarray study of OACs [4] with that of its high confi-
dence target genes identified by ChIP-seq analysis in
OE33 cells. Importantly, 64% of the FOXM1 target genes
exhibited highly correlated expression with FOXM1 across
cancer samples (R values >7; Figure 2A). Furthermore, this
correlation was maintained in both the OE33-specific and
cell type-independently bound FOXM1 target gene sub-
sets, albeit to a greater extent with the latter set of targets.
These results are therefore indicative of a role for FOXM1
in regulating a high proportion of its direct target genes in
OAC. To further substantiate this activating role for
FOXM1, we used the Nanostring nCounter gene expres-
sion assay to profile the effect of FOXM1 depletion on the
expression of a subset of its target genes in OE33 cells.
We focussed on genes whose expression was highly corre-
lated with FOXM1 expression in OAC (R values >7). The
majority of the genes commonly occupied by FOXM1
across cell types showed significant reductions in expres-
sion upon FOXM1 depletion (Figure 2B; left). The effect
on target gene expression from the OE33-specific category
was less pronounced but several genes exhibited reduced
expression following FOXM1 knockdown, most notably
NDE1 and UHRF1 (Figure 2B; right).
Together these results therefore identify the binding
regions constituting the FOXM1 cistrome in OAC-derived
OE33 cells, some of which appear to be preferentially
occupied in this cell type compared to U2OS cells. Loss
of function experiments demonstrates the importance
Figure 1 Identification of the FOXM1 cistrome in oesophageal-derived OE33 cells. (A) The genomic distribution of the 517 FOXM1 DNA
binding regions found in two independent ChIP-seq experiments in OE33 cells (left panel) compared to the background distribution of the same
genomic features across the whole genome (right panel). The core promoter corresponds to the 5′ untranslated region (UTR) and DNA sequences
1 kb upstream of the TSS. (B) The top 13 enriched GO terms for biological processes identified in the genes associated with the 517 FOXM1
binding regions are shown. Terms are sorted by -log10 P-value. (C) Heatmaps of the tag density profiles around the peaks identified only in OE33
cells (top panel) or U2OS cells (bottom panel) or in both OE33 and U2OS cells (middle panel) in the OE33 (1,716 peaks; blue) and U2OS (206 peaks;
red) ‘combined reads’ datasets. 5 kb upstream and 5 kb downstream of the peak summit (indicated by the arrow) are plotted. (D) Screenshots from
the UCSC browser showing examples of FOXM1 binding peaks for the indicated genes. Examples of OE33-specific and OE33/U2OS shared binding
peaks are shown. (E) ChIP-qPCR validation of FOXM1 binding to loci associated with the indicated genes in OE33 (red bars) and U2OS (blue bars) cells.
PLK1 distal is a negative control region not bound by FOXM1. Data are shown as means ± SD (n≥ 3).
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across OAC cancer samples is suggestive of a role for
FOXM1 in driving the expression of a large proportion
of its target gene network.
The expression of FOXM1 target genes and its
coregulators in OAC patient biopsies
Although our cross-correlation analysis of FOXM1 ex-
pression with that of its target genes in a publishedmicroarray study established a close relationship between
FOXM1 and the expression of many of its direct target
genes, the patient cohort was relatively homogenous, and
samples were derived from post-operative samples from
patients pre-treated with chemotherapy [4]. We therefore
used the Nanostring nCounter gene expression assay to
profile the expression of a panel of 49 “direct” FOXM1
targets across our own cohort of patients. 82 clinical sam-
ples were analysed: 58 of these were from OAC tissues
Figure 2 The role of FOXM1 in regulating its target genes. (A) Heatmap depicting mRNA expression levels of FOXM1 target genes in
oesophageal adenocarcinoma samples. Samples were ranked according to the expression of FOXM1 across 78 adenocarcinoma samples [4] and
genes ranked according to their similarity to FOXM1 expression across all samples (Pearson’s correlation coefficients >0.7 are shown). Dark squares
shown above each gene symbol indicate that the gene was in the OE33-U2OS “shared” FOXM1 target gene dataset. (B) Nanostring nCounter gene
expression analysis of mRNA levels of FOXM1 target genes in OE33 cells following transient transfection with siRNA directed against FOXM1 (siFOXM1,
blue bars), for targets shared between OE33 and U2OS cells or specifically found in OE33 cells. The mRNA count was normalised by the geometric
mean of ALAS1, GAPDH and HMBS expression. The mean count relative to control cells (siNTC, taken as 1, grey bars) of at least three biological
replicates is shown. Error bars indicate the standard deviation. Statistical significance is indicated (P-values: ** <0.01 and * <0.05).
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tissues taken from patients with histologically normal
oesophageal mucosa and no diagnosis of oesophageal
cancer. Basic demographics and, where appropriate,
clinical staging and treatment information for the 82
cases analysed is contained in Additional file 3: Table S2.
In addition to testing downstream targets, we also profiled
the expression of several FOXM1 co-regulatory partner
proteins to gain a picture of the broader regulatory cir-
cuitry that is operational in OAC. Here we focused on
members of the MMB and DREAM complexes which re-
ciprocally co-activate or repress FOXM1 target genes
[16,17]. Genes were grouped into those encoding MuvBcore complex components (LIN9, LIN37, LIN52, LIN54,
and RBBP4), DREAM-specific components (RBL2, E2F4
and TFDP1) and the MMB-specific component (MYBL2).
First, we asked whether FOXM1 expression was higher
in the OAC-derived samples, and we found it to be
expressed to significantly higher levels across cancer
samples (Additional file 2: Figure S2A; Figure 3). This is
in agreement with our previous observations in a differ-
ent collection of OAC biopsies [8]. Next, the expression
of the FOXM1 target gene cohort was clustered according
to expression similarities amongst the genes themselves
and also amongst patient samples (Figure 3; bottom
panel). The expression values of MMB/DREAM complex
Figure 3 Heatmap representation of expression of the FOXM1 regulatory network in OAC patient samples. Heatmap summary of
Nanostring nCounter gene expression analysis of 49 direct FOXM1 target genes (bottom panel) or genes encoding members of the MMB and
DREAM complex (top panel), in samples from normal and tumour tissues. The expression level of each gene is represented by the z-score of the
normalised mRNA level across all samples. The mRNA levels were normalised by the geometric mean of the GAPDH, ALAS1, PARPBP, HMBS and
SDHA internal reference genes. Blue and cream represent high and low expression respectively as indicated by the scale bar. Rows (representing
individual genes) and columns (representing individual tissue samples from normal (NRML) and tumour (OAC) tissues) are ordered by unsupervised
hierarchical clustering of the 49 FOXM1 target genes. Major clusters of genes are indicated (A-C) and samples are broadly categorised into clusters of
normal or tumour samples. Genes bound by FOXM1 in both OE33 and U2OS cells are marked by an orange dot. The position of FOXM1 is indicated
by the black arrow. Clinical information on overall (AJCC) tumour stage (early/late), T stage (early/late) and presence or absence of nodal or distant
metastasis is shown for each tumour sample above the heatmap (top four rows, coloured boxes). Darker coloured boxes represent late T/AJCC stage
or presence of nodal/distant metastasis and lighter coloured boxes represent early T/AJCC stage or absence of nodal/distant metastasis as is indicated
by the legend. Grey dots indicate samples from normal oesophageal tissue.
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ing heatmap and clustered according to similarity of ex-
pression only (Figure 3; top panel). Clustering analysis
provided a good separation of normal and tumour sam-
ples according to their gene expression profiles with only
three OAC cases clustering with the normal samples and
conversely one normal sample with the OAC samples.
Two separate clusters were observed for tumour samples.
However, no co-clustering of clinical features was ob-
served amongst the OAC samples (Figure 3, top rows).
Nevertheless, the FOXM1 target gene network was clearly
a good predictor of the presence of OAC. To determine
the generality of these findings, we also analysed the ex-
pression of the same set of FOXM1 target genes andMMB/DREAM complex components in a microarray
study across a different cohort of patients [4]. Again, the
FOXM1 target gene cohort was clustered according to ex-
pression similarities amongst the genes themselves and
also amongst patient samples (Additional file 2: Figure S2;
bottom panel) and a good separation between normal and
tumour samples was obtained. Thus, the FOXM1 target
gene expression profile provides a good overall indicator
of OAC presence but is not diagnostic of any particular
clinical feature of disease severity.
Next, correlations amongst FOXM1 targets with FOXM1
expression were examined and three broad clusters
were identified (Figure 3; vertical clustering). Cluster A
contains genes that show strong co-association with
Wiseman et al. Molecular Cancer  (2015) 14:69 Page 6 of 14FOXM1 expression in OAC and show clear evidence of
upregulation compared to normal samples. Interestingly,
this cluster contains all but one of the genes that we tested
which show binding of FOXM1 across different cell types
(Figure 3; orange dots. eg CCNB1 and UBE2C) and this
pattern is also seen in the independent microarray data set
(Additional file 2: Figure S2). Indeed further testing of
genes commonly occupied across cell types shows that the
majority of these are significantly upregulated across OAC
samples (Additional file 2: Figure S3B). Moreover, there
was a clear stepwise relationship between the magnitude
of FOXM1 overexpression and the expression levels of
members of this group of target genes in OAC (Figure 4A)
suggesting a causal link.
The genes in cluster B also show evidence of upregula-
tion in OAC, although the changes compared to normal
samples are less marked (Figures 3 and 4B). Again, there
is a clear relationship between the levels of FOXM1
expression and the magnitude of expression of genes
within this subset exemplified by HMGB3 and CDC25C
(Additional file 2: Figure S4A).
Finally cluster C contains two sub-categories of genes
(Figure 3), one of which shows little differences between
normal and tumour samples. The second subcategory
contains a reciprocal relationship between normal oeso-
phagous and OAC where expression is reduced in the
tumour samples, and hence shows an anti-correlation
with FOXM1 expression, despite representing direct tar-
gets (eg AGFG2 and CCDC85C)(Figure 3 and Additional
file 2: Figure S4B). Collectively, these data show that
FOXM1 target gene expression is generally upregulated
alongside FOXM1 expression, although different subclus-
ters can be identified with distinct expression profiles. Al-
though we see this association with FOXM1 expression,
the signatures that we observe might be reflective of the
fact that the cells within OACs are cycling more rather
than FOXM1 being a driving factor. We therefore also
analysed a group of genes previously shown to be regu-
lated at the G1-S transition [21]. Modest increases in
expression across this cohort in OAC were seen with the
expression of the key marker of the G1-S transition
CCNE1 barely altered in cancer samples and SERPINB3
being significantly downregulated (Additional file 2: Figure
S3C), indicating that there are not necessarily more cells
in the cell cycle in OAC tissues.
Having established that FOXM1 and its target genes
show strong co-association, we next turned to its core-
gulators in the MMB complex and the antagonistically
acting components of the DREAM complex. We pre-
dicted that either there should be no change in their
expression or there should be concomitant changes with
FOXM1 expression ie activating components should go
up and/or repressive components should go down in
cancer samples. Unexpectedly we saw components ofthe core MuvB complex both increase (eg LIN9) and
decrease (eg LIN54) in expression in OAC samples
(Figures 3 and 4C). Similarly, we also saw DREAM-
specific components both increase (eg E2F4) and to some
extent, decrease (eg RBL2) across cancers (Figures 3 and
4C). The MMB-specific component MYBL2 was signifi-
cantly upregulated across OAC samples (Figures 3 and
4C), and the degree of overexpression generally followed
the overexpression levels of FOXM1 (Additional file 2:
Figure S4C). A similar correlative pattern was seen for
LIN9 and E2F4 whereas the expression of LIN54 was
weakly anti-correlated with FOXM1 expression levels
(Additional file 2: Figure S4C). Importantly we found
the same correlative changes in MMB/DREAM complex
component expression in the microarray analysis of an
independent set of OAC samples (Additional file 2:
Figure S3D), although the overexpression of MYBL2 in
these tumours was less marked. Given these close asso-
ciations between FOXM1 expression and members of
the MMB and DREAM complexes, we also determined
whether the expression of one of the novel FOXM1 tar-
get genes that we identified, UHRF1, also correlated
with changes in expression of components of these
complexes. Positive correlations were seen with FOXM1,
MYBL2, LIN9 and E2F4 which all increase in OAC,
whereas a weaker negative correlation was seen with
LIN54 (Additional file 2: Figure S4D). Collectively, these
findings demonstrate some anticipated outcomes eg
co-overexpression of activating components of the MMB
complex but also some unexpected discoveries such as up-
regulation of DREAM-specific or downregulation of MuvB
core complex components (summarised in Figure 4D).
FOXM1 directly binds to LIN9
The co-upregulation of LIN9 and MYBL2 with FOXM1
in OAC patient samples suggested that one or both of
the proteins encoded by these genes might functionally
interact with FOXM1 either in the context of the entire
MMB complex or in subcomplexes. In the latter case,
direct interactions with FOXM1 would be anticipated.
Previous results have demonstrated that FOXM1 binds
to the MMB complex and this results in FOXM1 recruit-
ment to chromatin [16,17]. However, it was not clear
which subunit(s) is responsible for binding to FOXM1
and thereby nucleating its recruitment.
To determine whether either LIN9 or MYBL2/B-myb
interacted with FOXM1, we tested FOXM1 binding to
in vitro translated individual MMB complex components
using a GST pulldown assay with GST-FOXM1(1–367).
This N-terminal region of FOXM1 was previously
shown to be sufficient for binding to the MMB complex
[16]. Strong binding was only consistently obtained to
two different isoforms of Lin9 with weak or no binding
observed to MYBL2/B-myb or other MMB components
Figure 4 Box plot representation of the expression of FOXM1 regulatory network genes in OAC patient samples. (A-C) Box plots of
mRNA levels of the FOXM1 target genes in normal oesophageal (left panels) and oesophageal adenocarcinoma (OAC) tissue samples (right and
middle panels). Where indicated, the OAC samples are further partitioned according to high (right panel; n = 31) or low (middle panel; n = 27)
FOXM1 expression. High FOXM1 expression was defined as mRNA levels that were greater than two standard deviations and greater than
two-fold of the mean FOXM1 level in the normal tissues. Genes are grouped according to representing FOXM1 targets shared between OE33 and
U2OS cells (A), specifically bound in OE33 cells (B) or encoding components of the MMB and DREAM complexes (C). The mRNA level relative to
the median level of the normal tissues (taken as 1) is shown. Boxes represent the interquartile range and the median value is indicated by the
horizontal line. Open black circles represent outliers. The dotted line in (A) is the average median expression value of all the genes in the particular
sub-panel (value indicated in red). Statistical significance of the change in expression between OAC and normal tissue, normal and low FOXM1 OAC
tissue or low FOXM1 and high FOXM1 OAC tissue, is indicated in the rightmost panel of the two panels being compared (** P-value <0.01;
* P-value <0.05). (D) Summary of the changes in expression of genes encoding MMB/DREAM complex components in OAC samples
(red and blue represent down and up regulated in OAC respectively).
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interaction is direct, we repeated the assay with Lin9
expressed and purified from bacteria. Strong binding
was observed between FOXM1 and Lin9 (Figure 5B lane
12). Further mapping experiments demonstrated that
FOXM1 interacts with the N-terminal region of Lin9
encompassing the DIRP (Domain in Rb-related Pathway)
domain (Figure 5B, lane 9).
Having established LIN9 as the direct binding partner
of FOXM1, we depleted LIN9 in OE33 cells and tested
the expression of a subset of FOXM1 target genes.Generally, LIN9 depletion resulted in downregulation of
FOXM1 target genes with many being commonly down-
regulated upon FOXM1 depletion (Figure 5C and D).
However, there were differences in the magnitudes of
decrease observed in individual cases with genes like
HMGB3 being more sensitive to LIN9 depletion and
CDKN3 being more sensitive to FOXM1 depletion
(Figure 5C).
Collectively, these data show that FOXM1 and LIN9
interact directly and co-regulate a similar set of genes.
This helps provide a molecular rationale for why we
Figure 5 (See legend on next page.)
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Figure 5 FOXM1 and interactions with the MMB complex. (A) GST pulldown analysis using GST or GST-FOXM1(1–367) and the indicated
in vitro translated MMB and DREAM complex components. Precipitated and input in vitro translated proteins were detected by phosphorimaging
(top panel) and GST fusion proteins were detected by Coomassie blue staining (bottom panels). Arrow represents the position of the band
corresponding to full-length GST-FOXM1(1–367). (B) GST pulldown analysis using GST or GST-FOXM1(1–367) and the indicated bacterially
expressed and purified full-length and deleted Flag-tagged Lin9 proteins (shown diagrammatically at the top). FOXM1 and Lin9 derivatives
were detected by immunoblotting with anti-Flag (top) or anti-GST antibodies (bottom). The region of Lin9 which is sufficient for FOXM1
binding is boxed. (C) Nanostring nCounter gene expression assay of the indicated control or FOXM1 target genes following siRNA-mediated
knockdown of FOXM1 or LIN9. Data are shown as a heat map of fold change (log2) relative to a non-targeting siRNA control and are the average of
three independent experiments. Grey dots represent the identities of genes in the overlap of the Venn diagram in part (D). (D) Venn diagram of genes
showing significant (p < 0.05, t-test) changes in expression following knockdown of one of the two indicated factors. Note that ARHGAP19 changes in
opposite directions for each knockdown.
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two transcriptional regulators in OAC patients.
Clinical insights from the FOXM1 regulatory network
It is clear that the expression of FOXM1, several of its
co-regulatory partners and many of its target genes are
of potential diagnostic use for identifying the presence of
OAC. To further interrogate our data, we subdivided
our OAC samples as either early or late T stage, and also
whether metastases (local or distant) were present in the
patients. First we analysed the expression of MMB and
DREAM complex components and found that amongst
tumours, reduced levels of LIN54 are generally found in
tumours (Figure 4C) but lower levels are indicative of
late stage disease in patients with late T stage tumours
and local metastases (Figures 4C and 6A). A similar
trend was seen for RBL2, except that in this case, re-
duced expression was significant in patients with distant
metastases (Figure 6A). Other components of these
complexes which showed upregulation in OAC samples,
including FOXM1 itself, did not differ in their expres-
sion between patients with early or late stage cancer
(Additional file 2: Figure S5A). The lack of stage-specific
changes in FOXM1 expression is consistent with our pre-
vious data [8]. Thus while the expression of many MMB
and DREAM complex components is not changed accord-
ing to disease stage, reduced expression of a core compo-
nent of the MuvB complex (LIN54) and a DREAM-specific
component (RBL2) are good indicators of the presence of
late stage disease.
Next, we examined the expression of members of the
FOXM1 target gene network across patients from differ-
ent disease stages. In general the expression of FOXM1
target genes did not associate with disease severity. In-
deed, we were unable to find significant stage-specific
differences in expression in any of the FOXM1 targets
that were shared between OE33 and U2OS cells (data
not shown). However, several genes in the “OE33-specific”
FOXM1 target gene exhibited differential expression ac-
cording to disease stage. For example, UHRF1 and RGS3
are both overexpressed in general in cancers (Figure 4B;
Additional file 2: Figure S4B) but they showed evidence ofincreased expression in late stage disease (significantly
enhanced in patients with distant and local metastases
respectively) (Figure 6A). UHRF1 is particularly inter-
esting in this context given its recent identification as
an oncogene that drives DNA hypomethylation in cancer
cells [22]. In contrast, HIST1H3G showed significantly
reduced expression in patients with late T stage disease
(Figure 6A) and although generally highly expressed in
OAC (Figure 4B; Additional file 2: Figure S4B), both
C20orf72/MGME2 and SNX5 showed significantly reduced
expression when local metastases are present (Additional
file 2: Figure S5B). Interestingly, we also found that NUDT2
whose expression is generally decreased in OAC (Figure 4B)
shows reduced expression in late stage disease, which
reaches statistical significance in patients with distant me-
tastases (Figure 6A). Together these results identify several
FOXM1 target genes whose expression changes in OAC,
which are of potential value in predicting the presence of
late stage disease.
Discussion
FOXM1 overexpression has been observed in a variety
of different tumour types (reviewed in [7]) and our re-
cent work indicated that in the context of OAC, several
of its target genes, including PLK1, are co-ordinately
overexpressed in this cancer type [8]. However, it was
not known how FOXM1 contributes to tumourigenesis
in this context. To address this issue, we have extended
these studies to a broader cohort of FOXM1 target
genes, the majority of which are novel targets and have
not previously been studied in the context of cancer.
Here we demonstrate that there is a more widespread
co-ordinate upregulation across the FOXM1 target gene
network in OAC.
FOXM1 has previously been implicated in cell cycle
control [10] and many of its target genes have known or
suspected functions in the late G2 and early M phase
[16,17,19]. Many of this class of target genes are effi-
ciently bound by FOXM1 in both OE33 cells and the
non-OAC U2OS cells (eg CCNB1 and CENPF), indica-
tive of a core function for FOXM1 across cell types. This
class of target genes is generally co-upregulated with
Figure 6 Changes in the FOXM1 target gene network in late stage OAC. (A) Box plots of mRNA levels of the indicated genes in OAC tissue
samples grouped according to T stage, the presence of local metastases (absent, n = 18; present, n = 37) or the presence of distal metastases
(absent, n = 38; present, n = 18). Early and late T stage was defined as stage 1 or 2 disease (n = 16) and stage 3 or 4 disease (n = 32) respectively.
The mRNA level relative to the median level of normal tissues (taken as 1; grey lines) is shown. Boxes represent the interquartile range and the
median value is indicated by the horizontal line. Open black circles represent outliers. Statistical significance is indicated (** P-value <0.01; * P-
value <0.05). (B) Summary of the changes in expression of FOXM1 and genes encoding MMB/DREAM complex components in OAC samples (red
and blue represent down and up regulated in OAC respectively) leading to general upregulation of the FOXM1 target gene network.
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FOXM1 target genes, typified by HIST1H3G, that are
more efficiently bound by FOXM1 in OE33 cells, sug-
gesting a more cell type-specific activity for FOXM1.
Many of these genes are also co-ordinately deregulated
with FOXM1 in OAC, and in the case of HIST1H3G, a
lowering of expression towards the levels found in nor-
mal tissue is indicative of late stage disease. Reciprocally,
other targets like RGS3 are generally upregulated in
OAC but show higher levels in tumours with local metas-
tases. Thus, FOXM1 has potentially acquired new tissue/
cell type specific functions in OAC in keeping with thenovel recently identified roles of FOXM1 in gliomas,
breast cancer and lymphoblastomas through targeting dif-
ferent gene networks in each tumour type [13-15]. In the
latter cases, FOXM1 interacts with different transcription
factors to elicit its novel effects but it is unclear whether
re-direction of FOXM1 targeting is driven by any particu-
lar transcription factor in OAC or whether other mecha-
nisms might be operative.
The majority of the FOXM1 target genes that we have
discovered and investigated in the context of OAC are
novel target genes and have not been extensively studied
in the context of cancer. One such gene that stands out
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that drives DNA hypomethylation in hepatocellular car-
cinoma [22]. UHRF1 encodes a multi-domain protein in-
volved in histone ubiquitination and recruiting the DNA
methylase DNMT1 to chromatin during DNA replica-
tion, and hence plays a pivotal role in sculpting the epi-
genetic landscape [23]. UHRF1 had not previously been
linked to FOXM1 or OAC but has been shown to be
overexpressed in a wide range of other cancers [23] and
consistent with our observations of high levels in late
stage OAC, has also been shown to be a marker for
tumour aggressiveness in cervical cancer [24]. Among
the other genes that we linked to late stage disease, little
is known about their potential roles in other cancers
although NUDT2 has previously been shown to be up-
regulated in human breast carcinomas [25] whereas
SNX5 is upregulated in papillary thyroid carcinomas
[26]. Mechanistically, we have demonstrated that in
addition to FOXM1 binding to their regulatory regions,
FOXM1 and LIN9 are important activators of many of
these target genes (Figures 2B and 5C & D) indicating
that the LIN9-FOXM1 complex plays an important role
in upregulating these genes in OAC.
In addition to studying the FOXM1 target gene net-
work, we also studied the expression of MMB complex
components in OAC. Previous studies have implicated
FOXM1 and MYBL2 overexpression in a range of differ-
ent cancers (reviewed in [18]). In contrast little is known
about the expression of other core complex components
in cancers although LIN9 is part of the Mammaprint
breast cancer profile which is prognostic for metastatic
disease [27]. The MMB complex works synergistically
with FOXM1 to drive cell cycle gene expression [16,17],
it was expected that either there would be no change or
alternatively co-ordinate upregulation of the MMB com-
plex components. In the first scenario, FOXM1 could
use pre-existing MMB complex components to target
the same genes more efficiently and/or excess FOXM1
might then participate in new interactions and hence
deregulate a new target gene network. Overexpression of
the entire MMB complex would presumably facilitate
FOXM1 recruitment to cell cycle genes. However, al-
though we found co-ordinate upregulation of the MMB-
specific component MYBL2 with FOXM1, the MuvB
core subunit components LIN9 and LIN54 were differen-
tially expressed with LIN9 being co-ordinately upregulated
and LIN54 being downregulated in OAC (Figure 6B). Ul-
timately, this series of events coincides with the upregula-
tion of the FOXM1 target gene network and suggests a
co-operative mode of action. These findings on a central
FOXM1-LIN9-MYBL2/B-myb axis are consistent with the
recent finding that the human papillomavirus E7 protein
controls mitotic gene activation through interacting with
FOXM1, MYBL2/B-Myb and LIN9 components of theMMB complex [28]. However while LIN9 and MYBL2 up-
regulation in OAC might be explicable, the downregula-
tion of LIN54 is entirely unexpected. Both observations
suggest that in the context of OAC, different MMB-like
complexes might be forming with different stoichiome-
tries which likely contribute to the differential gene ex-
pression programmes we observe. Importantly, we show
that amongst MMB complex components, LIN9 is the
one that is directly bound by FOXM1. Thus, there is the
potential for the assembly of complexes containing these
two components in OAC. It is currently unclear which
other components are recruited in the context of OAC,
but presumably the reductions in LIN54 levels suggest it is
unlikely that LIN54 will play a part in driving OAC. In
OAC-derived cells, both FOXM1 and LIN9 co-ordinately
activate a subset of FOXM1 targets, consistent with the
observation that these interact directly and are co-
overexpressed in OAC, further supporting a co-regulatory
role in the context of OAC. However the role of LIN54 re-
mains enigmatic as it is also required for efficient FOXM1
target gene expression in OE33 cells (data not shown) and
yet shows an anti-correlation with FOXM1 target gene ex-
pression in OAC samples. It is possible that the overex-
pression of LIN9 and/or MYBL2 might over-ride the
requirement for LIN54 in this context. LIN54 has previ-
ously been implicated in targeting the MMB complex to
DNA [29], thus it is possible that the loss of LIN54 might
allow binding of FOXM1-MMB subcomplexes to alterna-
tive regulatory regions, either directly or through different
DNA binding proteins.
Collectively our data show that both the FOXM1 tar-
get gene network and its co-regulatory partner proteins
are deregulated in OAC. The expression of the FOXM1
target gene network is strongly predictive for the pres-
ence of OAC. Similarly the expression of FOXM1 itself
and several of its co-regulatory partners show good pre-
dictive power for diagnosing OAC. While the networks
do not give prognostic power, the expression of several
of the target genes we have studied provide indications
of disease stage.
Materials and methods
Tissue collection and cell lines
Ethical approval for collection of oesophageal tissue sam-
ples from patients at the Royal Albert Edward Infirmary,
Wigan and the Salford Royal Hospital were granted by the
ethics committees at Wrightington, Wigan and Leigh
NHS Foundation Trust (2007) and Salford Royal NHS
Foundation Trust (2010) respectively.
Biopsy tissue samples (~4 mm) were preserved in
RNAlater (Qiagen) or immediately snap-frozen in liquid
nitrogen and archived at −80°C. Normal control samples
were collected from patients with no macroscopic evi-
dence of oesophageal cancer. Patient demographics and
Wiseman et al. Molecular Cancer  (2015) 14:69 Page 12 of 14clinical details were collected. Patients were staged accord-
ing to standard specialist multidisciplinary team (MDT)
practice with computed tomography (CT), endoscopic
ultrasound (EUS) and positron emission tomography (PET)
as appropriate. Tumour stage was classified according to
the updated 7th Edition of the American Joint Committee
on Cancer (AJCC) staging system [30].
OE33 and U2OS cell lines were grown as described
previously [16,31].
RNA isolation and Nanostring nCounter expression analysis
Total cellular RNA was isolated from cell line and clinical
tissue samples as described previously [31]. When re-
quired, short interfering (si) RNAs directed against human
FOXM1, LIN9 and LIN54 (SMARTpools; Dharmacon), or
a non-targeting pool (Dharmacon) were used. Cells were
transfected using Lipofectamine RNAiMAX transfection
reagent (Invitrogen) and siRNA treatment was performed
with 100 pmol for 24 hrs prior to mRNA expression ana-
lysis. Sample hybridization, purification, immobilisation
and imaging were performed according to the manufac-
turer’s protocol (Nanostring Technologies).
Digital Analyser output reporter code count (RCC)
files were analysed using the nSolver Analysis software
(Nanostring Technologies), using default settings. Inbuilt
data analysis workflow wizards were used to perform
quality control, positive control normalisation and refer-
ence gene normalisation on the data. For each analysis
mRNA counts were normalised by positive control
spike-in probes supplied with the CodeSet and by the
geometric mean of the internal reference genes. Cell line
data was normalised using ALAS1, GAPDH and HMBS
internal reference genes. Five reference genes (SDHA,
ALAS1, GAPDH, HMBS and PARPBP) were used to
normalise the clinical samples data.
In knockdown experiments statistical significance was
calculated using an unpaired two-tailed Student’s T test
with a two sample equal variance. Gene expression data
comparing expression in different groups of clinical tis-
sue samples were represented with boxplots generated
using SPSS Statistics v20 software (IBM). Outliers repre-
sent values >1.5 interquartile ranges from the 25th or the
75th percentile (e.g. 75th percentile + (1.5 × IQR) and
25th percentile – (1.5× IQR)). Statistical significance was
assessed by the Mann Whitney U Test calculated using
SPSS Statistics v20. Heatmaps of gene expression in clin-
ical tissues quantified using the Nanostring nCounter
system were produced using the pheatmap: Pretty Heat-
maps software package in R (http://CRAN.R-project.org/
package=pheatmap).
ChIP and ChIP-seq analysis
ChIP-qPCR and ChIP-seq were carried out as described
previously [16]. For ChIP-seq, 3×107 cells, 3 μg antibody(FOXM1; Santa Cruz Biotechnology (sc- 502 X) or rabbit
IgG; Millipore (12–370)) and 30 μl Dynabeads were used
per experiment. Library preparation was performed using
the TruSeq ChIP Sample Preparation Protocol (Illumina)
and DNA libraries were sequenced using the Genome
Analyser IIx (Illumina).
Plasmids, protein purification and GST pulldown assays
pAS3091 (pET-30b-Lin9(1–270)), pAS3092 (pET-30b-
Lin9(135–405)), pAS3093 (pET-30b-Lin9(271–542)) or
pAS3094 (pET-30b-Lin9(full-length)) were created by
inserting Nde1/XhoI-cleaved PCR products (created using
the primer pairs ADS3727/ADS3731, ADS3728/ADS3732,
ADS3729/ADS3730 and ADS3727/ADS3730 respectively,
and pAS3078 as a template) into the same sites in
pET-30b.
GST-tagged FOXM1(1–367) protein was purified as
described previously [16]. To purify His tagged Lin9 pro-
teins, BL21-CodonPlus-RIL bacteria were transformed
with the following plasmids: pAS3091 (encoding Lin9
(1–270)), pAS3092 (encoding Lin9(135–405)), pAS3093
(encoding Lin9(271–542)) or pAS3094 (encoding full-
length Lin9). His-tagged proteins were purified using
Ni-Agarose (Qiagen) essentially according to the manu-
facturer’s instructions followed by dialysis into 1× PBS.
Glycerol was added to 30% final concentration for stor-
age at −80°C.
To make in vitro translated proteins, the following
plasmids were used (kindly provided by Kurt Engeland):
pAS3077 (pcDNA3.1-RbAp48), pAS3078 (pcDNA3.1-
Lin9 isoform 1), pAS3079 (pcDNA3.1-Lin9 isoform 2),
pAS3080 (pcDNA3.1-Lin54), pAS3081 (pcDNA3.1-Lin52),
pAS3082 (pcDNA3.1-Lin37), pAS3083 (pcDNA3.1-E2f4),
pAS3084 (pcDNA3.1-B-Myb), and pAS3085 (pcDNA3.1-
Dp1). The in vitro translation was performed using TNT
Quick Coupled Transcription/Translation Systems (Pro-
mega) according to the manufacturer’s protocol.
The GST-pull down experiments were performed as
previously described [16], using 500 ng of GST-FOXM1
(1-367) with 1 μl of IVT proteins or 1/10 of the eluate
of the His-tagged Lin9 proteins.
Bioinformatics analysis
Sequencing tags/reads from the FOXM1 ChIPseq ex-
periment in OE33 cells were aligned to the NBCI Build
hg18 of the human genome with Bowtie v0.12.7 [32]. Up
to two mismatches were allowed. Only reads that
uniquely mapped to the genome were preserved. Peak
calling was performed with MACS v1.4.2 software [33]
using default parameters. To identify high confidence
FOXM1 binding peaks, the MACS peak calling output
from two experimental replicates was used. Peaks that
were identified in both experimental replicates (overlap-
ping peaks) with a false discovery rate (FDR) <10 and a
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replicates were identified as significant high confidence
peaks. When determining the peak overlaps from each
analysis an in-house script was used to determine the
percentage of the region of the smaller peak that over-
lapped with the larger peak. Overlap cut-off threshold
was set to 50%, such that 50% of the smaller peak in one
replicate was required to overlap with the peak in the
other replicate to be considered an overlapping peak. To
identify high sensitivity FOXM1 binding events, reads
from two experimental replicates were pooled and peak
calling was performed again on the combined reads
dataset. Peaks with an FDR <10 and TD > 30 were de-
fined as significant high sensitivity peaks. An identical
analysis pipeline was performed on the FOXM1 ChIP-
seq data from U2OS cells ([16]; GSE38170). Gene anno-
tation was performed using an in-house script to identify
the closest gene to the peak summit using the co-
ordinates from the Refseq GH 18 v.55 protein coding
list. The nearest gene was ascribed to the binding peak
when the summit of the peak occurred within 5 kb up-
stream or 1 kb downstream of the transcription start site
(TSS). Additionally if the binding peak was within 1 kb
of the promoter region of any gene this was included.
Cis-regulatory element annotation system (CEAS) ana-
lysis [34] was performed using the Galaxy/Cistrome web
tool (http://cistrome.org/ap/) using the Build 36.3/hg 18
of the human genome and default settings. Gene ontol-
ogy (GO) analysis was performed using the GREAT web
application (http://bejerano.stanford.edu/great/public/
html/) [35] using NBCI Build 36.3/hg 18 of the human
genome. Tag density heatmaps and profiles were gener-
ated using Seqminer v.1.3.3e using default settings (peak
extensions 5 kb upstream and 5 kb downstream of the
peak summit and bin size 50 bp).
Processing of a microarray dataset profiling gene ex-
pression of 28 normal and 64 oesophageal adenocarcin-
oma samples (accession number: GSE13898) [4] and the
calculation of Pearson’s correlation coefficients (PCC) of
FOXM1 target genes to FOXM1 expression across tu-
mours was described previously [8]. Clustering and visu-
alisation of the expression levels of the FOXM1 target
genes were performed by MultiExperiment Viewer, a
part of TM4 microarray software suite [36].Additional files
Additional file 1: Table S1. FOXM1 binding regions identified using
ChIPseq in OE33 and U2OS cell lines. Data are shown according to
classification as high confidence (found in both replicates) or high
coverage (found when reads are combined from both replicates and
binding regions recalled).
Additional file 2: Supplementary Figures S1-5.Additional file 3: Table S2. Clinical details of the patient samples.
Patients are grouped by tissue type (normal oesophageal tissue and
oesophageal adenocarcinoma tissue). Basic demographic details are
shown for all patients. Median age and interquartile range (IQR) is shown.
Clinical staging and treatment details are provided for the oesophageal
adenocarcinoma group. The number of cases is shown with percentages
in brackets. Individual T, N, M stage and histologic grade of tumour is
shown as well as the overall American Joint Committee on Cancer (AJCC)
stage using the 2010 staging criteria. The number of cases with missing
data is indicated where necessary. One OAC sample was omitted from
the final Nanostring analysis as the gene expression changes showed this
to be an outlier.
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